1-3 of 3
Filippo G. de Braud
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial

Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Paola Tiberio, Marilena V. Iorio, Florentine Hilbers, Evandro de Azambuja, Lorena de la Peña, Miguel Izquierdo, Jens Huober, José Baselga, Martine Piccart, Filippo G. de Braud, Giovanni Apolone, Paolo Verderio, Maria Grazia Daidone
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (13): 3887–3895.
https://doi.org/10.1158/1078-0432.CCR-18-2507
Published: 01 July 2019
View articletitled, Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Open the PDF for Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

Laura W. Goff, Roger B. Cohen, Jordan D. Berlin, Filippo G. de Braud, Andrej Lyshchik, Cristina Noberasco, Francesco Bertolini, Marina Carpentieri, Corrado Gallo Stampino, Antonello Abbattista, Erjan Wang, Hossein Borghaei
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (9): 2146–2154.
https://doi.org/10.1158/1078-0432.CCR-15-1622
Published: 01 May 2016
View articletitled, A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Vanesa Gregorc, Filippo G. De Braud, Tommaso M. De Pas, Roberto Scalamogna, Giovanni Citterio, Alessandra Milani, Sabrina Boselli, Chiara Catania, Giovanni Donadoni, Gilda Rossoni, Domenico Ghio, Gianluca Spitaleri, Cristina Ammannati, Scialini Colombi, Federico Caligaris-Cappio, Antonio Lambiase, Claudio Bordignon
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1964–1972.
https://doi.org/10.1158/1078-0432.CCR-10-1376
Published: 31 March 2011
View articletitled, Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
Open the PDF for Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors in another window